A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients

A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients

Abstract Background There is no consensus regarding optimal treatment for peripheral T-cell lymphomas (PTCL), especially in relapsed or refractory cases, which have very poor prognosis and a dismal outcome, with 5-year overall survival of 30 %. Methods A multicenter prospective phase II trial was co...

Full description

Bibliographic Details
Main Authors: Cinzia Pellegrini, Anna Dodero, Annalisa Chiappella, Federico Monaco, Debora Degl’Innocenti, Flavia Salvi, Umberto Vitolo, Lisa Argnani, Paolo Corradini, Pier Luigi Zinzani, On behalf of the Italian Lymphoma Foundation (Fondazione Italiana Linfomi Onlus, FIL)
Format: Article
Language:English
Published: BMC 2016-04-01
Series:Journal of Hematology & Oncology
Subjects:
Peripheral T-cell lymphoma
Relapsed
Refractory
Gemcitabine
Romidepsin
Online Access:http://link.springer.com/article/10.1186/s13045-016-0266-1

Internet

http://link.springer.com/article/10.1186/s13045-016-0266-1

Similar Items